Publication Name	World Journal of Virology
Manuscript ID	70593
Country	India

Received	2021-08-07 16:29
Peer-Review Started	2021-08-07 16:33
To Make the First Decision
Return for Revision	2021-11-11 09:09
Revised	2021-11-22 18:26
Second Decision	2022-02-22 03:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-02-23 21:11
Articles in Press	2022-02-23 21:11
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-02-21 04:56
Typeset the Manuscript	2022-03-21 01:53
Publish the Manuscript Online	2022-03-22 04:46

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Letter to the Editor
Article Title	Therapeutic potential of N-acetyl cysteine during COVID-19 epoch
Manuscript Source	Unsolicited Manuscript
All Author List	Ajita Kapur, Munish Sharma and Geetanjali Sageena
Funding Agency and Grant Number
Corresponding Author	Geetanjali Sageena, PhD, Assistant Professor, Environmental Studies, Keshav Mahavidyalaya University of Delhi, H-4-5 Zone Pitampura, New Delhi 110034, India. geetanjali.sageena@keshav.du.ac.in
Key Words	N-acetyl cysteine; COVID-19; Coagulopathy; Therapeutic potential
Core Tip	Risk of coagulopathy is noteworthy in coronavirus disease 2019 (COVID-19) and cerebral haemorrhage could be a potential risk in COVID-19 patients receiving N-acetyl cysteine (NAC). Results of well-designed randomized controlled trials should be awaited before NAC becomes a common practice for prophylaxis and treatment of patients with COVID-19.
Publish Date	2022-03-22 04:46
Citation	Kapur A, Sharma M, Sageena G. Therapeutic potential of N-acetyl cysteine during COVID-19 epoch. World J Virol 2022; 11(2): 104-106
URL	https://www.wjgnet.com/2220-3249/full/v11/i2/104.htm
DOI	https://dx.doi.org/10.5501/wjv.v11.i2.104

Full Article (PDF)	WJV-11-104.pdf
Full Article (Word)	WJV-11-104.docx
Manuscript File	70593_Auto_Edited-JRF-Filipodia CL.docx
Answering Reviewers	70593-Answering reviewers.pdf
Audio Core Tip	70593-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	70593-Conflict-of-interest statement.pdf
Copyright License Agreement	70593-Copyright license agreement.pdf
Peer-review Report	70593-Peer-review(s).pdf
Scientific Misconduct Check	70593-Bing-Fan JR-2.png
Scientific Editor Work List	70593-Scientific editor work list.pdf
CrossCheck Report	70593-CrossCheck report.pdf
CrossCheck Report	70593-CrossCheck.png